Literature DB >> 7500896

Epidemiologic aspects of infective endocarditis in an urban population. A 5-year prospective study.

H Hogevik1, L Olaison, R Andersson, J Lindberg, K Alestig.   

Abstract

A prospective study of the epidemiology of infective endocarditis (IE) in a well-defined urban population of 428,000 inhabitants during a 5-year period was carried out. All patients were treated in the same institution, and history, diagnostic procedures, and treatment were standardized. Of 233 consecutive suspected episodes of IE, 127 fulfilled the modified von Reyn criteria. After patients not living in the defined area were excluded, 99 episodes in 90 patients were analyzed in the epidemiologic part of the study. Of these, 33 episodes were definite endocarditis, verified by surgery or autopsy; 35 probable; and 31 possible endocarditis episodes. Another 34 episodes were found retrospectively and are included in the incidence calculation. The crude incidence was calculated to be 6.2/100,000 inhabitants per year, which is high compared to earlier studies. Adjusted to the population of Sweden, the incidence was 5.9/100,000 inhabitants per year. The annual incidence was higher for women, 6.6/100,000, than for men, 5.8/100,000. In the oldest age-group (80-89 years) the annual incidence was 22/100,000 in the prospective study and 30/100,000 if retrospective cases were included. Contrary to almost all other studies, we did not find a male predominance among our cases. Only 7% of patients were intravenous drug abusers, and 15% had a prosthetic valve. The most common bacteria were methicillin-susceptible Staphylococcus aureus (31%) and alpha-streptococci (28%); 12% of episodes were culture negative. The mortality from IE in the population was 1.4/100,000 inhabitants per year. A higher-than-expected incidence of IE was found, especially among older patients and women.

Entities:  

Mesh:

Year:  1995        PMID: 7500896     DOI: 10.1097/00005792-199511000-00003

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  53 in total

1.  Nonculture Laboratory Methods for the Diagnosis of Infectious Endocarditis.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-06       Impact factor: 3.725

2.  Staphylococcus aureus, Platelets, and the Heart.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-08       Impact factor: 3.725

3.  Infective endocarditis and perivalvular abscess: a dangerous duo.

Authors:  Stephen D Shafran
Journal:  CMAJ       Date:  2002-07-09       Impact factor: 8.262

4.  Update on echocardiography in the management of infective endocarditis.

Authors:  John Francis Sedgwick; Darryl John Burstow
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

5.  The changing face of infective endocarditis.

Authors:  E Cecchi; M Imazio; R Trinchero
Journal:  Heart       Date:  2006-10       Impact factor: 5.994

6.  Characteristics and analysis of risk factors for mortality in infective endocarditis.

Authors:  Hakan Leblebicioglu; Hava Yilmaz; Yesim Tasova; Emine Alp; Rabin Saba; Rahmet Caylan; Mehmet Bakir; Ayhan Akbulut; Bilgin Arda; Saban Esen
Journal:  Eur J Epidemiol       Date:  2006       Impact factor: 8.082

7.  Mitral valve endocarditis leading to acute myocardial and cerebellar infarction in a young adult.

Authors:  F Breuckmann; C K Naber; D Boese; A Lind; H Wieneke; J Barkhausen; R Erbel
Journal:  Clin Res Cardiol       Date:  2006-09-08       Impact factor: 5.460

Review 8.  Epidemiology and antibiotic treatment of infective endocarditis: an update.

Authors:  Bruno Hoen
Journal:  Heart       Date:  2006-11       Impact factor: 5.994

Review 9.  The Changing Epidemiology of Infective Endocarditis in the Twenty-First Century.

Authors:  J Ambrosioni; M Hernandez-Meneses; A Téllez; J Pericàs; C Falces; J M Tolosana; B Vidal; M Almela; E Quintana; J Llopis; A Moreno; José M Miro
Journal:  Curr Infect Dis Rep       Date:  2017-05       Impact factor: 3.725

10.  NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults.

Authors:  Clint S Schmidt; C Jo White; Ashraf S Ibrahim; Scott G Filler; Yue Fu; Michael R Yeaman; John E Edwards; John P Hennessey
Journal:  Vaccine       Date:  2012-10-22       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.